Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05881668
Other study ID # MSC-EV of ThirdSunYatSen
Secondary ID
Status Withdrawn
Phase Phase 1
First received
Last updated
Start date September 30, 2023
Est. completion date April 30, 2025

Study information

Verified date October 2023
Source Third Affiliated Hospital, Sun Yat-Sen University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Acute-on-chronic liver failure refers to a liver failure syndrome in which some patients with chronic liver disease with relatively stable liver function suffer from acute liver decompensation and liver failure due to the effects of various acute injury factors. Liver transplantation is the only curative treatment for this type of end-stage liver disease. The potential of MSCs to repair or regenerate damaged tissue and suppress immune responses makes them promising in the treatment of liver diseases, especially in the field of liver transplantation. Many studies have shown that MSC-based therapies can reduce the symptoms of liver disease due to their paracrine effects. Therefore, compared to the cells they derive from, mesenchymal stem cells-derived extracellular vesicles (MSC-EV) are gradually gaining attention for their enhanced safety, as they do not replicate or cause microvascular embolism, and can be easily stored without losing their properties. It represents a novel and effective cell-free therapeutic agent as alternative to cell-based therapies for liver diseases, and liver failure was also concerned. This study was designed to evaluate the safety and tolerability of MSC-EV in acute-on-chronic liver failure after liver transplantation.


Description:

In the MSC-EV group (experimental group), 15 patients will receive a single injection of MSC-EV after their first liver transplantation. In the non-MSC-EV group (control group), 15 patients will not receive MSC-EV therapy after their first liver transplantation. The outcome of the experimental group will be compared with that of similar control patients undergoing liver transplantation but who will not receive MSC-EV. Both of the two groups will receive standard immunosuppressive therapy( a regimen based on tacrolimus (TAC), mycophenolate mofetyl (MMF) and steroids). Patients participated in the experimental cohort will be infused with a single dose of 10 E10 MSC-EV particles per 100ml, at an appropriate time during the first 1-5 days after transplantation.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date April 30, 2025
Est. primary completion date September 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - aged 18-60 years; - Acute on chronic liver failure-which is characterized by acute hepatic insult manifesting as jaundice (serum total bilirubin [TBil] = 10×ULN umol/L) and coagulopathy (international normalized ratio [INR] = 1.5 or prothrombin activity < 40%), complicated within 4 weeks by ascites and/or encephalopathy as determined by physical examination, in patients with previously diagnosed or undiagnosed chronic liver disease; Requiring liver transplantation due to acute on chronic liver failure; - Obtain the patients' consent after informing patients of the purpose and method of the clinical trial; Exclusion Criteria: - Past history of malignant disease - Active uncontrolled infection; - Combined transplantation - EBV-negative; - HIV or HCV positive; - Retransplantation;

Study Design


Intervention

Biological:
MSC-EV
10 E10 MSC-EV particles per 100ml for a single dose. No prior HLA matching between MSC donors and recipients or liver donors

Locations

Country Name City State
China Third Affiliated Hospital, Sun Yat-Sen University Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Third Affiliated Hospital, Sun Yat-Sen University

Country where clinical trial is conducted

China, 

References & Publications (3)

Detry O, Vandermeulen M, Delbouille MH, Somja J, Bletard N, Briquet A, Lechanteur C, Giet O, Baudoux E, Hannon M, Baron F, Beguin Y. Infusion of mesenchymal stromal cells after deceased liver transplantation: A phase I-II, open-label, clinical study. J Hepatol. 2017 Jul;67(1):47-55. doi: 10.1016/j.jhep.2017.03.001. Epub 2017 Mar 9. — View Citation

Lin BL, Chen JF, Qiu WH, Wang KW, Xie DY, Chen XY, Liu QL, Peng L, Li JG, Mei YY, Weng WZ, Peng YW, Cao HJ, Xie JQ, Xie SB, Xiang AP, Gao ZL. Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure: A randomized controlled trial. Hepatology. 2017 Jul;66(1):209-219. doi: 10.1002/hep.29189. Epub 2017 May 27. — View Citation

Psaraki A, Ntari L, Karakostas C, Korrou-Karava D, Roubelakis MG. Extracellular vesicles derived from mesenchymal stem/stromal cells: The regenerative impact in liver diseases. Hepatology. 2022 Jun;75(6):1590-1603. doi: 10.1002/hep.32129. Epub 2021 Nov 27. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with MSC-EV infusion-related toxicity as assessed by CTCAE v4.0. Incidence, timing and severity of any clinical complication related to MSC-EV infusion, such as tympanic body temperature, heart rate, mean arterial blood pressure and allergy, as assessed by CTCAE v4.0 . 24 hours after injection
Primary Aspartate aminotransferase (AST) Collect clinical results reflecting liver function 6 months after transplantation
Primary Alanine aminotransferase (ALT) Collect clinical results reflecting liver function 6 months after transplantation
Primary Bilirubin level Collect clinical results reflecting liver function 6 months after transplantation
Primary International normalized ratio (INR) Collect clinical results reflecting liver function 6 months after transplantation
Primary carbohydrate Compound antigen (GGT) level Collect clinical results reflecting liver function 6 months after transplantation
Primary Adverse events Any adverse events which may related to MSC-EV infusion 6 months
Secondary Number of survived patients at 1 year after liver transplantation, according to the follow-up results. Patients who are surviving, as assessed by outpatient or telephone follow-up, at 1 year after liver transplantation 12 months
Secondary Number of survived grafts at 1 year after liver transplantation, according to the follow-up results. Surviving patients with primary and functional grafts, as assessed by outpatient or telephone follow-up, at 1 year after liver transplantation. 12 months
Secondary Recipient's immune function, as assessed by analysis of immune cell subsets from biopsy or blood samples ,at months 1-6 after liver transplantation. A series of immune cell subsets will be analyzed, including T cells (CD3+), CD4+ T cells (CD3+ CD4+ lymphocytes), CD8+ T cells (CD3+ CD8+ lymphocytes), naïve CD4+ T cells (CD4+ CD45RAhigh lymphocytes), memory CD4+ T cells (CD4+ CD45RO+ lymphocytes), natural killer (NK) cells (CD3- CD56+ lymphocytes), as well as B cells (CD19+ lymphocytes) 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05793983 - S100A8/A9 and Innate Immunity in Liver Disease
Completed NCT03641872 - A Validation Cohort for ACLF Diagnosis and Prognosis
Not yet recruiting NCT03863002 - Safety and Efficacy of Mesenchymal Stem Cell Transplantation for Acute-on-Chronic Liver Failure Phase 1/Phase 2
Recruiting NCT05786859 - The Efficacy and Safety of Rifaximin Treatment Early Phase 1
Completed NCT03312036 - HEpatic Regeneration With COupled Plasma Filtration and Adsorption for Liver Extracorporeal Detoxification N/A
Completed NCT04959110 - Citrate Pharmacokinetics in Critically Ill Liver Failure Patients Receiving CRRT N/A
Completed NCT02457637 - Chinese CLIF-C Acute-on-Chronic Liver Disease and Liver Failure Study
Completed NCT03281265 - A Retrospective Multicenter Study of HBV-related Pre-acute-on-chronic Liver Failure in China N/A
Recruiting NCT03281252 - A Prospective Study of Evaluation of Minor Bleeding and Utility of Bleeding Criteria in Acute-on-chronic Liver Failure Patients in China N/A